Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00992459 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 46
- Enrollment target
NCT00992459 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 46 participants.
The verdict
NCT00992459, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 46 participants
- Enrollment target
Study Summary
This was a randomized, active-controlled, double-blind, cross-over study designed to enroll subjects with UCDs who are being treated with NaPBA.
Interventions
- DRUG HPN-100
- DRUG Buphenyl (NaPBA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00992459
The ClinicalTrials.gov registry entry for NCT00992459 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HPN-100 is the first listed.
NCT00992459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00992459 about?
NCT00992459 is a clinical study titled "Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders". This was a randomized, active-controlled, double-blind, cross-over study designed to enroll subjects with UCDs who are being treated with NaPBA.
What is the current status of trial NCT00992459?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 46 participants. The study started on 2009-10. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00992459?
The interventions under investigation include: HPN-100 (DRUG), Buphenyl (NaPBA) (DRUG).
Who is sponsoring clinical trial NCT00992459?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.